<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01603095</url>
  </required_header>
  <id_info>
    <org_study_id>111-901</org_study_id>
    <secondary_id>2017-000701-21</secondary_id>
    <nct_id>NCT01603095</nct_id>
  </id_info>
  <brief_title>A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia</brief_title>
  <official_title>A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, multinational study to collect consistent baseline growth measurements on&#xD;
      pediatric patients with Achondroplasia being considered for subsequent enrollment in future&#xD;
      studies sponsored by BioMarin. No study drug is administered.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">February 2021</completion_date>
  <primary_completion_date type="Actual">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Collection of consistent growth measurements</measure>
    <time_frame>Assessed every 3 months for up to 84 months</time_frame>
    <description>Patients will be screened and undergo a series of growth measurements on Day 1 and every 3 months thereafter. No study drug is administered.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">363</enrollment>
  <condition>Achondroplasia</condition>
  <arm_group>
    <arm_group_label>Growth measurements</arm_group_label>
    <description>Approximately 500 patients will be enrolled. Patients from birth to &lt;= 17 years on the date of consent will be enrolled. Approximately equal numbers of boys and girls will be enrolled.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Approximately 500 patients will be enrolled. Patients from birth to &lt;= 17 years, inclusive,&#xD;
        on the date of consent will be enrolled. Approximately equal numbers of boys and girls will&#xD;
        be enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Parent(s) or guardian(s) willing and able to provide signed informed consent after the&#xD;
             nature of the study has been explained and prior to performance of any&#xD;
             research-related procedure. Also, willing and able to provide written assent (as&#xD;
             needed) after the nature of the study has been explained and prior to performance of&#xD;
             any research-related procedure.&#xD;
&#xD;
          -  Aged 0 to &lt;= 17 years, inclusive, at study entry.&#xD;
&#xD;
          -  Have ACH, documented by clinical diagnosis&#xD;
&#xD;
          -  Are ambulatory and able to stand without assistance (not applicable for infants)&#xD;
&#xD;
          -  Are willing and able to perform all study procedures as physically possible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have hypochondroplasia or short stature condition other than ACH (e.g., trisomy 21,&#xD;
             pseudoachondroplasia)&#xD;
&#xD;
          -  Have any of the following disorders:&#xD;
&#xD;
               -  Hypothyroidism&#xD;
&#xD;
               -  Insulin-requiring diabetes mellitus&#xD;
&#xD;
               -  Autoimmune inflammatory disease&#xD;
&#xD;
               -  Inflammatory bowel disease&#xD;
&#xD;
               -  Autonomic neuropathy&#xD;
&#xD;
          -  Have an unstable clinical condition likely to lead to intervention during the course&#xD;
             of the study, including progressive cervical medullary compression&#xD;
&#xD;
          -  Growth plates have fused&#xD;
&#xD;
          -  Have a history of any of the following:&#xD;
&#xD;
               -  Renal insufficiency&#xD;
&#xD;
               -  Anemia&#xD;
&#xD;
          -  Cardiac or vascular disease, including the following:&#xD;
&#xD;
               -  Cardiac dysfunction (abnormal echocardiogram [ECHO] including left ventricle [LV]&#xD;
                  mass) at Screening Visit&#xD;
&#xD;
               -  Hypertrophic cardiomyopathy&#xD;
&#xD;
               -  Congenital heart disease&#xD;
&#xD;
               -  Cerebrovascular disease, aortic insufficiency&#xD;
&#xD;
               -  Clinically significant atrial or ventricular arrhythmias&#xD;
&#xD;
          -  Current treatment with antihypertensive medications angiotensin-converting enzyme&#xD;
             (ACE) inhibitors, angiotensin II receptor blockers, diuretics, beta-blockers,&#xD;
             calcium-channel blockers, cardiac glycosides, systemic anticholinergic agents, any&#xD;
             medication that may impair or enhance compensatory tachycardia, drugs known to alter&#xD;
             renal function that is expected to continue for the duration of the study&#xD;
&#xD;
          -  Have been treated with growth hormone, insulin-like growth factor 1 (IGF-1), or&#xD;
             anabolic steroids in the previous 6 months or long-term treatment (&gt; 3 months) at any&#xD;
             time&#xD;
&#xD;
          -  Have had regular long-term treatment (&gt; 1 month) with oral corticosteroids (low-dose&#xD;
             ongoing inhaled steroid for asthma is acceptable)&#xD;
&#xD;
          -  Concomitant medication that prolongs the QT/QTc interval within 14 days or 5&#xD;
             half-lives, whichever is longer, before the Screening visit&#xD;
&#xD;
          -  Have used any other investigational product or investigational medical device for the&#xD;
             treatment of ACH or short stature&#xD;
&#xD;
          -  Have had bone-related surgery or expected to have bone-related surgery during the&#xD;
             study period. Subjects with previous limb-lengthening surgery may enroll if surgery&#xD;
             occurred at least 18 months prior to the study and healing is complete without&#xD;
             sequelae.&#xD;
&#xD;
          -  Have any condition that, in the view of the Investigator, places the patient at high&#xD;
             risk of poor compliance with the visit schedule or of not completing the study.&#xD;
&#xD;
          -  Concurrent disease or condition that, in the view of the Investigator, would interfere&#xD;
             with study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>BioMarin Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Research Center Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours/Alfred I. duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin, Children's Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Murdoch Children's Research Institute</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Children's Medical Center</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokushima University Hospital</name>
      <address>
        <city>Tokushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala de Traumatologica I Medicina de l'Esport</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>MÃ¡laga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acibadem University School of Medicine</name>
      <address>
        <city>Istanbul</city>
        <zip>34752</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Children's NHS Foundation Trust</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Germany</country>
  </removed_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 11, 2012</study_first_submitted>
  <study_first_submitted_qc>May 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2012</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Achondroplasia</keyword>
  <keyword>dwarfism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Achondroplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

